Myriad Genetics Statistics
Share Statistics
Myriad Genetics has 92.18M
shares outstanding. The number of shares has increased by 0.89%
in one year.
| Shares Outstanding | 92.18M |
| Shares Change (YoY) | 0.89% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 677 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 5.59M, so 6.06% of the outstanding
shares have been sold short.
| Short Interest | 5.59M |
| Short % of Shares Out | 6.06% |
| Short % of Float | 8.56% |
| Short Ratio (days to cover) | 2.59 |
Valuation Ratios
The PE ratio is -6.02 and the forward
PE ratio is 29.73.
Myriad Genetics's PEG ratio is
-0.05.
| PE Ratio | -6.02 |
| Forward PE | 29.73 |
| PS Ratio | 2.1 |
| Forward PS | 0.4 |
| PB Ratio | 2.02 |
| P/FCF Ratio | -8.6 |
| PEG Ratio | -0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Myriad Genetics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.01 |
| Quick Ratio | 1.87 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.82 |
| Debt / FCF | -0.83 |
| Interest Coverage | -88.76 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $278,962.96 |
| Profits Per Employee | $-97,518.52 |
| Employee Count | 2,700 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 10.74 |
Taxes
| Income Tax | 1.1M |
| Effective Tax Rate | -0.42% |
Stock Price Statistics
The stock price has increased by -82.99% in the
last 52 weeks. The beta is 2.02, so Myriad Genetics's
price volatility has been higher than the market average.
| Beta | 2.02 |
| 52-Week Price Change | -82.99% |
| 50-Day Moving Average | 7.52 |
| 200-Day Moving Average | 16.19 |
| Relative Strength Index (RSI) | 27.96 |
| Average Volume (20 Days) | 1,908,457 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of 753.2M
and earned -263.3M
in profits. Earnings per share was -3.18.
| Revenue | 753.2M |
| Gross Profit | 517M |
| Operating Income | -257.4M |
| Net Income | -263.3M |
| EBITDA | -186.1M |
| EBIT | -259.3M |
| Earnings Per Share (EPS) | -3.18 |
Full Income StatementBalance Sheet
The company has 132.1M in cash and 152.1M in
debt, giving a net cash position of -20M.
| Cash & Cash Equivalents | 132.1M |
| Total Debt | 152.1M |
| Net Cash | -20M |
| Retained Earnings | -629.5M |
| Total Assets | 1.08B |
| Working Capital | 138.9M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -110.9M
and capital expenditures -73.3M, giving a free cash flow of -184.2M.
| Operating Cash Flow | -110.9M |
| Capital Expenditures | -73.3M |
| Free Cash Flow | -184.2M |
| FCF Per Share | -2.22 |
Full Cash Flow StatementMargins
Gross margin is 68.64%, with operating and profit margins of -34.17% and -34.96%.
| Gross Margin | 68.64% |
| Operating Margin | -34.17% |
| Pretax Margin | -34.81% |
| Profit Margin | -34.96% |
| EBITDA Margin | -24.71% |
| EBIT Margin | -34.17% |
| FCF Margin | -24.46% |
